• Journal of Power Electronics
• /
• 제16권1호
• /
• pp.268-276
• /
• 2016

A hybrid sinusoidal-pulse current (HSPC) charging method for the Li-ion batteries in electric vehicle applications is proposed in this paper. The HSPC charging method is based on the Li-ion battery ac-impedance spectrum analysis, while taking into account the high power requirement and system integration. The proposed HSPC method overcomes the power limitation in the sinusoidal ripple current (SRC) charging method. The charger shares the power devices in the motor inverter for hardware cost saving. Phase shifting in multiple pulse currents is employed to generate a high frequency multilevel charging current. Simulation and experimental results show that the proposed HSPC method improves the charger efficiency related to the hardware and the battery energy transfer efficiency.

• Biotechnology and Bioprocess Engineering:BBE
• /
• 제9권1호
• /
• pp.7-11
• /
• 2004

Leukotactin-1 (Lkn-1), a human CC chemokine, has been demonstrated to induce chemotaxis of neutrophils, monocytes, eosinophils and Iym phocytes and has been shown to suppress colony formation of hematopoietic stem and progenitor cells (HSPC) in vitro and in vivo. The temporal suppression of HSPC by chemokines could potentially be applicable for various indications, such as the protection of HSPC from the several anti-proliferating chemotherapeutics in cancer treatments. In order to evaluate the protective effects on myeloid progenitor cells, the recombinant Lkn-1 was produced by Pichia pastoris and tested with cyclophosphamide, cytotoxic chemotherapeutics. The pretreatment of Lkn-1 increased the number of HSPC in bone marrow as well as the potency of resulting progenitor cells after the treatment of cyclophosphamide. Af-ter the first cycle of cyclophosphamide treatment these protections of HSPC correlated with the increased number of white blood cells and neutrophils in the peripheral blood. In lethal conditions created by the repeated administration of cyclophosphamide, the treatment of Lkn-1 enhanced the survival of mice, suggesting the potential use of Lkn-1 as the protective agent for HSPC from various cytotoxic insults.

• BMB Reports
• /
• 제50권3호
• /
• pp.138-143
• /
• 2017

Ovariectomy-induced bone loss is related to an increased deposition of osteoclasts on bone surfaces. We reported that the 36-amino-acid-long neuropeptide Y (NPY) could mobilize hematopoietic stem/progenitor cells (HSPCs) from the bone marrow to the peripheral blood by regulating HSPC maintenance factors and that mobilization of HSPCs ameliorated low bone density in an ovariectomy-induced osteoporosis mouse model by reducing the number of osteoclasts. Here, we demonstrated that new NPY peptides, recombined from the cleavage of the full-length NPY, showed better functionality for HSPC mobilization than the full-length peptide. These recombinant peptides mediated HSPC mobilization with greater efficiency by decreasing HSPC maintenance factors. Furthermore, treatment with these peptides reduced the number of osteoclasts and relieved ovariectomy-induced bone loss in mice more effectively than treatment with full-length NPY. Therefore, these results suggest that peptides recombined from full-length NPY can be used to treat osteoporosis.

• Molecules and Cells
• /
• 제41권8호
• /
• pp.753-761
• /
• 2018

Tumor necrosis factor receptor-associated factor 6 (TRAF6) is identified as a signaling adaptor protein that regulates bone metabolism, immunity, and the development of several tissues. Therefore, its functions are closely associated with multiple diseases. TRAF6 is also involved in the regulation of hematopoiesis under steady-state conditions, but the role of TRAF6 in modulating hematopoietic stem and progenitor cells (HSPCs) during the developmental stages remains unknown. Here, we report that the deletion of TRAF6 in hematopoietic lineage cells resulted in the upregulation of HSPCs in the fetal liver at the prenatal period. However, in the early postnatal period, deletion of TRAF6 drastically diminished HSPCs in the bone marrow (BM), with severe defects in BM development and extramedullary hematopoiesis in the spleen being identified. In the analysis of adult HSPCs in a BM reconstitution setting, TRAF6 played no significant role in HSPC homeostasis, albeit it affected the development of T cells. Taken together, our results suggest that the role of TRAF6 in regulating HSPCs is altered in a spatial and temporal manner during the developmental course of mice.

• 한국생물공학회:학술대회논문집
• /
• 한국생물공학회 2001년도 추계학술발표대회
• /
• pp.775-778
• /
• 2001

Pichia pastoris에서 생산된 rtLkn-1 은 농도에 따라 CFU의 colony 형성을 억제하였으며, 마우스와 인간 골수 세포에서 항암제에 의한 stem cell 및 progenitor cell의 사멸을 억제하였고 이것은 항암제가 작용하는 동안 세포 주기를 일시적으로 휴지기로 유도하였기 때문으로 사료된다.

• BMB Reports
• /
• 제47권4호
• /
• pp.192-196
• /
• 2014

RNA polymerase II carboxyl-terminal domain (pol II CTD) phosphatases are a newly emerging family of phosphatases that are members of DXDX (T/V). The subfamily includes Small CTD phosphatases, like SCP1, SCP2, SCP3, TIMM50, HSPC129 and UBLCP. Extensive study of SCP1 has elicited the diversified roles of the small C terminal domain phosphatase. The SCP1 plays a vital role in various biological activities, like neuronal gene silencing and preferential Ser5 dephosphorylation, acts as a cardiac hypertrophy inducer with the help of its intronic miRNAs, and has shown a key role in cell cycle regulation. This short review offers an explanation of the mechanism of action of small CTD phosphatases, in different biological activities and metabolic processes.

• BMB Reports
• /
• 제54권1호
• /
• pp.59-69
• /
• 2021

The ability to read, write, and edit genomic information in living organisms can have a profound impact on research, health, economic, and environmental issues. The CRISPR/Cas system, recently discovered as an adaptive immune system in prokaryotes, has revolutionized the ease and throughput of genome editing in mammalian cells and has proved itself indispensable to the engineering of immune cells and identification of novel immune mechanisms. In this review, we summarize the CRISPR/Cas9 system and the history of its discovery and optimization. We then focus on engineering T cells and other types of immune cells, with emphasis on therapeutic applications. Last, we describe the different modifications of Cas9 and their recent applications in the genome-wide screening of immune cells.

• 폴리머
• /
• 제29권3호
• /
• pp.277-281
• /
• 2005

비바이러스성 DNA 전달체 중에서 최근 양이온성 고분자와 양이온성 리피드들은 많이 연구되어 왔다. 본 연구에서는 비바이러스성 유전자 전달체로서 양이온성 고분자인 폴리에틸렌이민(PEI)을 리피드에 수식하여 더 효과적인 전달체를 제조하고자 하였다. 새로운 양이온성 리피드(PEI-DSPE)는 1,2-디아실-sn-글리세로-3-포스포에탄올아민(DSPE)과 PEI를 이용하여 고수율로 합성하였다. 1,2-디스테아로일-sn-글리세로-3-포스포콜린(DSPC), L-$\alpha$-포스파티딜콜린(소이-하디드로제네티드) (HSPC), 콜레스테롤(CHOL) 및 합성된 PEI-DSPE를 이용하여 리포좀을 제조하였다. 리포좀 제조는 리피드 함량에 대해 양이온성이 도입된 PEI-DSPE의 양을 증가시키며 수행하였다. 제조된 리포좀의 크기는 PEI-DSPE의 첨가량이 증가할수록 감소하였으며 리포좀의 표면전하 또한 양의 값으로 증가됨을 관찰할 수 있었다. PEI-DSPE 양적 변화에 따라 제조된 리포좀을 이용하여 DNA의 복합체 형성에 관한 결과 사용된 리포좀의 함량이 증가할수록 DNA와의 복합체 형성이 용이함을 전기영동 및 형광 측정을 통해 관찰할 수 있었으며 형성된 복합체가 사용된 리포좀 함량이 증가할수록 양이온적 성질이 증대됨을 관찰할 수 있었다. 그러므로 본 연구에서 합성한 PEI-DSPE를 사용하여 제조된 리포좀이 유전자 전달체로서의 가능성을 갖고 있음을 확인할 수 있었다.

• 대한화학회지
• /
• 제57권4호
• /
• pp.493-498
• /
• 2013

리포솜은 표적 약물을 봉입하여 병소에 안전하게 전달할 수 있는 약물전달체로서 연구되고 있다. 그러나 일반적인 리포솜은 표적부위에서 약물방출이 제한적인 문제점이 있다. 따라서 본 연구에서는 리포솜의 안정성을 향상시키고 표적부위에서 외부 초음파로부터 약물의 방출을 극대화시키기 위하여 하이드록시아파타이트(hydroxyapatite, HA)가 코팅된 리포솜을 개발하였다. 대조군 리포솜은 인지질과 콜레스테롤을 이용하여 제조하였고, 대조군 리포솜의 표면에 칼슘 아세테이트, 포스포릭에시드, 그리고 25% 암모니아용액을 이용하여 HA를 코팅하였다. 모델 약물로는 독소루비신을 사용하였다. HA코팅 리포솜의 크기는 120 nm 이었고, 약물봉입효율은 95% 이상이었다. 30% 혈장용액 내에서 HA코팅 리포솜의 입자크기는 일정한 상태를 유지하였으며, 대조군 리포솜은 크기가 1.4배 증가하였다. 외부 초음파 자극에 의한 리포솜으로부터 약물 방출을 유도한 후, 방출된 약물의 세포 이입율은 HA 코팅된 리포솜이 3배 이상 대조군 리포솜에 비하여 증가하였다. 본 연구에서는 외부 초음파 자극에 의하여 리포솜으로부터 약물의 방출을 극대화시키기 위한 초음파 민감형 리포솜을 개발하였고, 본 제형은 표적부위에서 약물의 방출을 효과적으로 제어하기 위한 분야에 활용이 가능할 것이다.

• Archives of Pharmacal Research
• /
• 제28권5호
• /
• pp.626-635
• /
• 2005

Liposome as a carrier of topotecan (TPT), a promising anticancer drug, has been reported in attempt to improve the stability and antitumor activity of TPT. However, the biodistr ibution pattern of TPT liposome in vivo and PEG-modified liposome containing TPT have not been studied systemically. In this paper, the in vitro stability and in vivo biodistribution behavior of several liposomes containing TPT with different lipid compositions and PEG-modification were studied. Compared with the 'fluid' liposome (S-Lip) composed of soybean phosphatidylcholine (SPC), the 'solid' liposome (H-Lip) composed of hydrogenated soybean phosphatidylcholine HSPC decreased the leaking efficiency of TPT from liposome and enhanced the stability of liposome in fetal bovine serum (FBS) or human blood plasma (HBP). The results of biodistribution studies in S$_{180}$ tumor-bearing mice showed that liposomal encapsulation increased the concentrations of total TPT and the ratio of lactone form in plasma. Compared with free TPT, S-Lip and H-Lip resulted in 5- and 19- fold increase in the area under the curve (AUC$_{0\rightarrow\propto}$), respectively. PEG- modified H-Lip (H-PEG) showed 3.7-fold increase in AUC$_{0\rightarrow\propto}$ compared with H-Lip, but there was no significant increase in t$_{1/2}$ and AUC$_{0\rightarrow\propto}$ for PEG-modified S-Lip (S-PEG) compared with S-Lip. Moreover, the liposomal encapsulation changed the biodistribution behavior, and H-Lip and H-PEG dramatically increased the accumulation of TPT in tumor, and the relative tumor uptake ratios were 3.4 and 4.3 compared with free drug, respectively. There was also a marked increase in the distribution of TPT in lung when the drug was encapsulated into H-Lip and H-PEG. Moreover, H-PEG decreased the accumulation of TPT in bore marrow compared with unmodified H-Lip. All these results indicated that the membrane fluidity of liposome has an important effect on in vitro stability and in vivo biodistribution pattern of liposomes containing TPT, and PEG-modified 'solid' liposome may be an efficient carrier of TPT.